Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515

Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510



LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

Alston & Bird LLP		
2. Address Check if different than previously reported 601 Pennsylvania Ave., NW, 10th Floor, Washington,	DC 20004-2601	
Principal Place of Business (if different from line 2) City: Atlanta State/	Zip (or Country) GA/30309-3424	
4. Contact Name Telephone	E-mail (optional)	5. Senate ID#
Jonathan M. Winer (202) 756-334	jwiner@alston.com	1182
7. Client Name Self U.S. Pharmacopeia		6. House 1D #
10. Check if this is a Termination Report	Date 06/30/05	11. No Lobbying
INCOME OR EXPENSES - Complete Eithe	r Line 12 OR Line 13	
INCOME OR EXPENSES - Complete Eithe 12. Lobbying Firms	r Line 12 OR Line 13 13. Organiza	ations
12. Lobbying Firms INCOME relating to lobbying activities for this reporting period was:	13. Organization of the second section of the second section is a second section of the section of t	
12. Lobbying Firms INCOME relating to lobbying activities for this reporting period was: Less than \$10,000	13. Organization of the state o	vities for this rep
12. Lobbying Firms INCOME relating to lobbying activities for this reporting period was: Less than \$10,000 \$\sigma \text{\$\sigma} \$	13. Organization of the state o	ivities for this rep benses (nearest \$20.0 ck box to indicate
12. Lobbying Firms INCOME relating to lobbying activities for this reporting period was: Less than \$10,000 \$10,000 or more \$\frac{1}{\text{lncome (nearest \$20,000)}}\$ Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all	13. Organiza EXPENSES relating to lobbying active period were: Less than \$10,000 \$10,000 or more \$\frac{1}{2} \times \frac{1}{2} \text{Exp}\$ 14. REPORTING METHOD. Che accounting method. See instructions \$\infty \text{Method A. Reporting amounts were accounted as the counting method.}\$	ivities for this represents \$20.0 ck box to indicate for description of
12. Lobbying Firms INCOME relating to lobbying activities for this reporting period was: Less than \$10,000 \$10,000 or more \$\Begin{array}{c} \sigma \left\ \lef	13. Organiza EXPENSES relating to lobbying active period were: Less than \$10,000 \$10,000 or more \$\frac{1}{2} \times \frac{1}{2} \text{Exp}\$ 14. REPORTING METHOD. Che accounting method. See instructions \$\infty \text{Method A. Reporting amounts were accounted as the counting method.}\$	venses (nearest \$20,0 ck box to indicate for description of using LDA definitunder section 603
12. Lobbying Firms INCOME relating to lobbying activities for this reporting period was: Less than \$10,000 \$10,000 or more \$\frac{1}{\text{lncome (nearest \$20,000)}}\$ Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying	13. Organiza EXPENSES relating to lobbying active period were: Less than \$10,000 \$10,000 or more \$\infty\$ \$\frac{\text{Exp}}{\text{Exp}}\$ 14. REPORTING METHOD. Che accounting method. See instructions \$\infty\$ Method A. Reporting amounts to the method by the country of the method and the country of t	enses (nearest \$20 ck box to indicate for description under section 60 cde

Filing #a8575bcf-aff9-466f-96c8-a97d7cc89f89 - Page 1 of 10

~.6	I				
Printed Name and Title	,	Jonathan M. Winer, Pa	rtner		

LD-2 (REV. 6/98)

Registrant Name	Alston & Bird LLP	Client Name	U.S. Pharmacopeia
engaged in lobbying		ing the reporting period	ct the general issue areas in which the r . Using a separate page for each code
15. General issue are	ea code MMM (on	e per page)	
16. Specific lobbyin Issues related to to prescription drug to	he implementation of Medicar	re Modernization Act of 200	03 (Public Law 108-173) and rate in
17. House(s) of Con	gress and Federal agencie	s contacted	Check if None
CMS 18. Name of each in	ndividual who acted as a lo	obbyist in this issue area	
	Name		Covered Official Position (if applicable)
Colin Roskey		Senate I	Finance Comm-Health Policy Adv & Cnsl
M. Lynn Sykes			
Thomas A. Scully		Centers	for Medicare & Medicaid Svcs-Admin
Jennifer L. Butler			
Erin Darling			
David Hebert, Marc	Scheineson		
Jennifer W. Bell	••••		Finance Committee - Health Policy Adv.
1.	oreign entity in the specific is	ssues listed on line 16 abov	ve Check if None Date 7. 29.05
Signature / / /	~ · · · · · · · · · · · · · · · · · · ·		Date / \ \ \ / \ \

Filing #a8575bcf-aff9-466f-96c8-a97d7cc89f89 - Page 3 of 10

Form LD-2 (Rev.6/98)

Page _

Registrant Name	Alston & Bird LLP	Client Name	U.S. Pharmacopeia
	behalf of the client du	ring the reporting period.	t the general issue areas in which the r Using a separate page for each code
15. General issue area	code MED (or	ne per page)	
16. Specific lobbying	issues		
Issues related to the prescription drug be		re Modernization Act of 2003	(Public Law 108-173) and rate in
17. House(s) of Congr	ress and Federal agenci	es contacted	Check if None
CMS 18. Name of each independent	ividual who acted as a l	obbyist in this issue area	
	Name		Covered Official Position (if applicable)
Colin Roskey	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Senate Fi	nance Comm-Health Policy Adv & Cnsl
M. Lynn Sykes	*********************************		
Thomas A. Scully		1	or Medicare & Medicaid Svcs-Admin
Jennifer L. Butler			
Erin Darling	***************************************		
David Hebert, Marc Sc	heineson	;	
Jennifer W. Bell			inance Committee - Health Policy Adv.
	eign entity in the specific i	issues listed on line 16 above	Check if None

Filing #a8575bcf-aff9-466f-96c8-a97d7cc89f89 - Page 5 of 10

Form LD-2 (Rev.6/98)

Page _

Registrant Name	Alston & Bird LLP	Client Name	U.S. Pharmacopeia
engaged in lobbying o		ring the reporting period.	t the general issue areas in which the r Using a separate page for each code
15. General issue area	a code HCR (or	ne per page)	
16. Specific lobbying		re Modernization Act of 2003	3 (Public Law 108-173) and rate in
prescription drug be			
17. House(s) of Cong	gress and Federal agenci	es contacted \Box	Check if None
CMS			
18. Name of each inc		obbyist in this issue area	
Colin Roskey	Name	Senate Fi	Covered Official Position (if applicable) inance Comm-Health Policy Adv & Cnsl
M. Lynn Sykes			
Thomas A. Scully			or Medicare & Medicaid Svcs-Admin
Jennifer L. Butler			
Erin Darling			
David Hebert, Marc S			
Jennifer W. Bell		Senate F	inance Committee - Health Policy Adv.
19. Interest of each for	eign entity in the specific i	ssues listed on line 16 above	e 🗹 Check if None
Signature	Ham Filing #a8575bcf-aff9-466f-	- 96c8-a97d7cc89f89 - Page 7	Date 7. 29.05

Form LD-2 (Rev.6/98)

Page _

	Alston & Bird LLP	Client Name	U.S.	Pharmacopeia	
nformation Up	date Page - Comple	te ONLY where regist	ration information has c	hanged.	
20. Client new address					
**	place of business (if different		4-420	***************************************	
City		State/Zip (or C	ountry)		
22. New general descrip	otion of client's business or ac	ctivities			
LOBBYIST UPD 23. Name of each p Alicia Ziemieck	reviously reported indiv	ridual who is no longer	expected to act as a lobby	vist for the client	
AFFILIATED Ol 25. Add the follow	ng issues previously rep RGANIZATIONS ing affiliated organization			Principal Place of Bu	
Name				(city and state or cou	
26. Name of each	·	anization that is no long	er affiliated with the regi	strant or client	
FOREIGN ENTIT					
FOREIGN ENTIT 27. Add the follow Name	ing foreign entities	Address	Principal place of business (city and state or country)	Amount of contribution for lobbying activities	

7. 29.05 Filling #a8575bcf-aff9-466f-96c8-a97d7cc89f89 - Page 9 of 10

oignaturev	-			
Printed Name and Title_	JONATHAM M WWOL	Pmonon	 	
Form LD-2 (Rev. 6/98)				Page _

Form LD-2 (Rev. 6/98)